Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21. - Lim S; Reynolds J; Quach H; Hutchinson A; Kerridge I; Janowski W; Bergin K; Spencer A (British journal of haematology, 2024)